Where does the US get most of its insulin from?


Editorial team Published on

The U.S. produces almost 100% of the insulin supply it uses domestically through the "Big Three" pharmaceutical manufacturers—Eli Lilly, Novo Nordisk, and Sanofi—which manufacture the vast majority of their U.S.-bound products within the country or rely on specialized global active pharmaceutical ingredient (API) and finished dose supply chains.

  • Domestic Production: Eli Lilly, Novo Nordisk, and Sanofi produce nearly all the insulin consumed in the United States, with major manufacturing facilities located stateside (such as Eli Lilly’s heavy investments in Indiana).
  • Global API and Finished Product Imports: While most finished products are made or packaged for the U.S. market locally, the U.S. also imports components and finished doses from abroad—historically sourcing active pharmaceutical ingredients (API) heavily from Denmark (over 90%) and finished dosage forms (FDF) largely from Germany (around 73%), alongside emerging imports from European and Asian suppliers.